1.65
+0.05(+3.13%)
Currency In USD
| Previous Close | 1.6 |
| Open | 1.58 |
| Day High | 1.68 |
| Day Low | 1.57 |
| 52-Week High | 8.08 |
| 52-Week Low | 1.17 |
| Volume | 215,128.05 |
| Average Volume | 470,005 |
| Market Cap | 36.19M |
| PE | -0.18 |
| EPS | -9.29 |
| Moving Average 50 Days | 1.71 |
| Moving Average 200 Days | 2.27 |
| Change | 0.06 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $9.38 as of March 04, 2026 at a share price of $1.655. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $2.41 as of March 04, 2026 at a share price of $1.655.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
GlobeNewswire Inc.
Feb 19, 2026 12:00 PM GMT
Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer’s dementia Large patient population affected by Alzheimer’s agitation, with approximately ~100 million a
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
GlobeNewswire Inc.
Feb 12, 2026 12:00 PM GMT
Third party commercial assessment shows larger than expected potential total addressable market for IGALMI® in the at-home setting Strong prescriber interest, patient demand, and positive payer feedback on formulary coverage NEW HAVEN, Conn., Feb. 1
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
GlobeNewswire Inc.
Jan 20, 2026 12:00 PM GMT
sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI® Submission timeline supports potential approval of IGALMI® label expansion as early as year-